Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: FLO-PRED

« Back to Dashboard
Flo-pred is a drug marketed by Taro and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

The generic ingredient in FLO-PRED is prednisolone acetate. There are seventy-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the prednisolone acetate profile page.

Summary for Tradename: FLO-PRED

Suppliers: see list1

Pharmacology for Tradename: FLO-PRED

Clinical Trials for: FLO-PRED

A Comparison of Three Different Formulations of Prednisolone Acetate 1%
Status: Completed Condition: Glaucoma; Cataract

Prednisolone Priming Study in Patients With Chronic Hepatitis B
Status: Recruiting Condition: Chronic Hepatitis B

Biomarkers of Prednisolone Treatment (P05888)
Status: Completed Condition: Insulin Resistance; Hyperglycemia; Glucose Intolerance

Preoperative Methylprednisolone in Endovascular Aortic Repair
Status: Completed Condition: Abdominal Aortic Aneurysms

The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia
Status: Completed Condition: Eosinophilic Pneumonia; Chronic Disease

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Status: Terminated Condition: Multiple Sclerosis

Methylprednisolone N Acetylcysteine in Hepatic Resections
Status: Terminated Condition: Ischemic Reperfusion Injury; Insufficiency; Hepatic, Postoperative; Liver Tumour

A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
Status: Completed Condition: Eye Infections; Postoperative Complications

Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis
Status: Completed Condition: Progressive Multiple Sclerosis

Prednisolone Pharmacokinetics in Severe Asthma
Status: Recruiting Condition: Asthma

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
prednisolone acetate
SUSPENSION;ORAL022067Jan 17, 2008RXYes6,656,482<disabled>Y<disabled>
prednisolone acetate
SUSPENSION;ORAL022067Jan 17, 2008RXYes6,399,079<disabled>Y<disabled>
prednisolone acetate
SUSPENSION;ORAL022067Jan 17, 2008DISCNNo7,799,331<disabled>Y<disabled>
prednisolone acetate
SUSPENSION;ORAL022067Jan 17, 2008RXYes5,881,926<disabled>Y<disabled>
prednisolone acetate
SUSPENSION;ORAL022067Jan 17, 2008DISCNNo6,656,482<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn